PRINCETON, New Jersey — Venture fund Domain Associates has closed a $500 million fund to invest in early-stage drug and medical device companies with “meaningful portion of its efforts going towards the diagnostics and instrumentation sector.”
The fund is the 24-year-old company’s eighth round. It has offices in San Diego as well as Princeton, and much of its active portfolio is based in California. Other companies include Apnex Medical in St. Paul, Minnesota, and Esperion Therapeutics in Plymouth, Michigan.
Its notable exits includes the biopharmaceutical company BiPar’s sale to Sanofi-aventis and testing company GeneOhm Sciences’ sale to Becton-Dickinson.
In addition to investing in companies, Domain stated it will continue to create companies through the money in its fund.
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=b3f00e02-aa9d-4984-8102-451c3eeac12a)
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.
By Chris Seper MedCity News
Chris Seper is the CEO at MedCity Media, which publishes MedCityNews.com. He is also a senior writer at MedCity News. Reach him at chris@medcitynews.com.More posts by Author
- Get Livefyre
- FAQ
